• 1998 – Present: A practicing physician, board certified in internal medicine and board eligible in  pediatrics. 

• 2013 – Present: Investigator in more than 50 research trials and co-author of four publications. 

• 2008: Co-founder of Physicians Quality Care, a unique urgent care, primary care, and occupational medicine clinic, which provides patients a more personal experience than what is typically offered in a traditional clinic. The clinic has grown with two locations and three work-site clinics and employs 90 people. 

• 2018 – Present: Clinical practice now focused on treating patients with complex multisystem and fatiguing illnesses, such as Myalgic Encephalomyelitis, Fibromyalgia, Dysautonomia, and Long COVID.  

• 1989: Bachelor of Science, Biology, Union University, Jackson, Tennessee.

• 1993: Medical Degree, University of Tennessee College of Medicine, Memphis, Tennessee.

• 1993-1997: Residency in Internal Medicine and Pediatrics at The University of Tennessee.

• Haffizulla, Jason, MD; Aaron Hartman, MD; Melanie Hoppers, MD; Harvey Resnick, MD; Steve Samudrala, MD; Christine Ginocchio, PhD; Matthew Bardin, PharmD; Prof Jean-Francois Rossignol, MD. (2014). Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomized, placebo-controlled, phase 2B/3 trial. The Lancet: Infectious Disease, 14(7), p609-618.

• Co-author on the manuscript “A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care” (reference number: NMED-BC109541), which was recently submitted to Nature Medicine. 

• Drain, Paul; Madhavi Ampajwala; Christopher Chappel, Andre Gvozden, Melanie Hoppers, Melody Wang, Robert Rosen, Stephen Young, Edward Zissman, Muchalina Montano. (2020). A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care.

• J.E. Ellis, R.A Sulaiman, M. Hoppers, M. Ampajwala, S. Young, P.Drain. (2021). Performance of the LumiraDx SARS-CoV-2 Antigen Test when used for detection of COVID-19 infection in asymptomatics. ECCMID.

• Le Bonheur Children’s Hospital, Pediatric Flu Study.

• Physicians Quality Care, CDC Flu Surveillance Study.

• Jackson Clinic, Otitis Media, Antibiotic Therapy.

• A randomized, double-blind, placebo-controlled study of Nitazonxanide in adults and adolescents with acute uncomplicated influenza.

• A multi-center, observational, descriptive study to assess the prevalence of CKD in adult patients with type 2 diabetes and to assess and characterize the proportion of patients with undiagnosed CKD as treated in routine primary care clinical practice conditions.

• A randomized, double-blind, double dummy, placebo-controlled study of the safety and efficacy of Mucinex (2400 mg/d) and Immediate-Release Guaifenesin (800mg/d) in the treatment of symptoms of acute respiratory tract infections for 7 days.

• A Phase 1-2, randomized, double-blind, placebo-controlled, multi-center study evaluating the safety and pharmacokinetics of different dosing regimens of Favipiravir in healthy adult subjects and adult subjects with uncomplicated influenza.

• A randomized, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy, safety and tolerability of Eluxadoline in the treatment of patients with diarrhea-predominant irritable bowel syndrome.

• A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Ranolazine Monotherapy in subjects with type 2 diabetes mellitus.

• A Phase 2 randomized, double-blind, placebo-controlled, parallel-arm study to investigate the efficacy and safety of inhaled Laninamivir Octanoate TwinCaps Dry Powder Inhaler in adults with symptomatic influenza A or B infection.

• A randomized, multi-center phase in an open-label, active comparator trial to assess the efficacy and safety of two regimens of Bucillamine 100mg tablets as compared to Colchicine 0.6mg tablets for the treatment of an acute gout flare in subjects with moderate to severe gout.

• A Phase 3, multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of IV and oral Delafloxacin compared with Vancomycin + Aztreonam in patients with acute bacterial skin and skin structure infections.

• A Phase 3, multi-center, randomized, double- blind, placebo-controlled study to evaluate the efficacy and safety of K-103-IP compared with placebo for the treatment of mild to moderate acute pain associated with ankle strain or sprain.

• A Phase 2, randomized, double-blind, placebo-controlled, parallel-arm study to investigate the efficacy and safety of inhaled Laninamivir Octanoate TwinCaps Dry Powder Inhale in adults with symptomatic influenza A or B infection.

• A randomized, multi-center, Phase 2, open-label, active-comparator trial to assess the efficacy and safety of two regimens of Bucillamine 100mg tablets as compared to Colchicine 0.6mg tablets for the treatment of an acute gout flare in subjects with moderate to severe gout.

• A Phase 3, multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of IV and oral Delafloxacin compared with Vancomycin + Aztreonam in patients with acute bacterial skin and skin structure infections.

• A Phase 3, multi-center, randomized, double- blind, placebo-controlled study to evaluate the efficacy and safety of K-103-IP compared with placebo for the treatment of mild to moderate acute pain associated with ankle strain or sprain.

• A randomized, double-blind, Phase 2 study comparing the efficacy, safety, and tolerability of combination antivirals Amantadine, Ribavirin, (Osetlamivir) versus Oseltamivir for the treatment of influenza in adults at risk for complications.

• A Phase 3 randomized, double-blind placebo-controlled trial to evaluate the efficacy and safety of Nitazoxanide and Nitazoxanide plus Oseltamivir in the treatment of acute uncomplicated influenza.

• A Phase 3 randomized, double-blind, active-controlled, multi-center study of the long-term safety and efficacy of subcutaneous administration of Tanezumab in subjects with osteoarthritis of the hip or knee.

• A randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of Toujeo compared to commercially available basal insulins for initiation of therapy in insulin naïve patients with controlled type 2 diabetes mellitus.

• A 24-week international, multi-center, randomized, open-label, active-controlled, parallel group, Phase 3b trial with a 28-week extension to evaluate the efficacy and safety of Saxagliptin co-administered with Dapagliflozin compared to insulin Tlargine in subjects with type 2 diabetes who have inadequate glycemic control on metformin with or without sulfonylurea therapy.

• A Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of Nitazoxanide in the treatment of acute uncomplicated influenza.

• A 6-week, randomized, double-blind, placebo- and active-controlled, parallel group, dose ranging study to evaluate the efficacy and safety of 4 doses of CHF 5259 pMDI (Glycopyrronium Bromide) in subjects with chronic obstructive pulmonary disease (COPD).

• A randomized, double-blinded, adaptive Phase 2 study to evaluate the safety and efficacy of Oral Omadacycline and Oral Nitrofurantoin in the treatment of female adults with cystitis.

• Observational study of patients with hypothyroidism switching from Levothyroxine to Desiccated Thyroid Extract.

• A Phase 3, randomized, multicenter, parallel-group, double-blind, double-dummy study in adolescent and adult female participants comparing the efficacy and safety of Gepotidacin to Nitrofurantoin in the treatment of uncomplicated urinary tract infection (acute cystitis).

• MTG-022: Translational Medicine: Discovery and evaluation of Biomarkers/ Pharmacogenomics for the diagnosis and personalized management of patients under Protocol MT0580.

• A multi-center COVID-19 study conducted to evaluate the performance of the Acucy® SARS-CoV-2 antigen test in point-of-care locations.

• A multi-center, randomized, double-blind, placebo-controlled study of Adalimumab or placebo in patients with mild-moderate COVID-19.

• A Phase 2/3 seamless, randomized, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the treatment of symptomatic, non-hospitalized adults with mild to moderate COVID-19. 

• A Phase 3 randomized, double-blinded, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for post-exposure prevention of SARS-CoV-2 infection in household contacts to a confirmed SARS-CoV-2 infected individual. 

• A Phase 3, randomized, double-blind, placebo controlled trial to evaluate the efficacy and safety of Nitazoxanide in the treatment of uncomplicated influenza.

• A Phase 3b, multicenter, randomized, double-blind, placebo-controlled, clinical efficacy study of Baloxavir Marboxil for the reduction of direct transmission of influenza from otherwise healthy patients to household contacts.

• MTG-022: Translational Medicine: Discovery and Evaluation of Biomarkers/ Pharmacogenomics for the diagnosis and Personalized Management of Patients Under Protocol MT0618.

• MTG-022: Translational Medicine: Discovery and Evaluation of Biomarkers/ Pharmacogenomics for the diagnosis and personalized management of patients under Protocol MT0597.

• MTG-022: Translational Medicine: Discovery and Evaluation of Biomarkers/ Pharmacogenomics for the diagnosis and personalized management of patients under Protocol MT1410.

• Research and development study in frozen serum, frozen plasma, and nasal swabs of patients diagnosed with COVID-19 under Protocol MT0300.

• Vaccine and therapeutic development study in fresh and frozen serum from patients who have recovered from COVID-19 infection under Protocol MT1560.

• A Phase 3, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSKs meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults.

• MTG-022: Translational Medicine: Discovery and Evaluation of Biomarkers/ Pharmacogenomics for the diagnosis and personalized management of patients under Protocol MT6065.
  n A multi-center Covid-19 study conducted to evaluate the agreement between fingerstick whole blood, venous whole blood, plasma and serum as determined on the LumiraDx Point of Care SARS-CoV-2 Ab test and to evaluate the ease of use at point-of-care sites.

• A multi-center COVID-19 study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 Ag test at-point-of-care testing sites.

• A Phase 2/3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ADG20 in the prevention of COVID-19 (EVADE).

• CS-1223-01: A multi-center study conducted to evaluate the performance of the VitaPCRTM Flu A&B Assay at point-of-care testing sites.

• MTG-022: Translational Medicine: Discovery and Evaluation of Biomarkers/ Pharmacogenomics for the diagnosis and personalized management of patients under Protocol MT1733.

• A 52-week, randomized, double-blind, double-dummy, placebo- and active-controlled (Roflumilast, Daliresp® 500µg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with chronic obstructive pulmonary disease (COPD) and chronic bronchitis.

• A study to test the performance and demonstrate effectiveness of the NOWDiagnostics Inc. (NOWDx) COVID-19 test for the detection of antibodies in response to SARS-CoV-2 infection.

• A Phase 2b double-blind, randomized, placebo-controlled, parallel-group study of efficacy and safety of Norketotifen (NKT) in the treatment of acute uncomplicated influenza-like illness (ILI).

• A multi-center COVID-19 study conducted to evaluate fingerstick whole blood on the Easy Check Plus COVID-19 IgM/IgG test and to evaluate the ease of use at point-of-care sites.

• A multi-center study conducted to evaluate the performance of the VitaPCRTM Flu A&B Assay at point-of-care testing sites.

• Protocol 2020-9835: Qualitative study on a symptoms questionnaire for use in outpatients with COVID-19.

• Clinical biospecimen procurement to support advancements in Medical Diagnoses of Diseases Project # 060-INF-13 Coronavirus Disease 2019 (COVID-19).

• MTG-022: Translational Medicine: Discovery and Evaluation of Biomarkers/ Pharmacogenomics for the diagnosis and personalized management of patients under Protocol MT1410 Cohort 3.

• Alinity m Resp-4-Plex Specimen Collection Protocol.

• A Phase 3b, multi-center, randomized, double-blind, placebo-controlled, clinical-efficacy study of Baloxavir Marboxil for the reduction of direct transmission of influenza from otherwise healthy patients to household contacts.

• A Phase 2/3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the Monoclonal Antibody Study Drug in the prevention of COVID-19.

• “Clinical Biospecimen Procurement to Support Advancements in Medical Diagnoses of Diseases” Project # 060-INF-12 Coronavirus Disease 2019 (COVID-19).

• MTG-022: Translational Medicine: Discovery and Evaluation of Biomarkers/ Pharmacogenomics for the diagnosis and personalized management of patients under Protocol MT6020.

• Abbott RealTime SARS-CoV-2 Specimen Collection Protocol V560-02-20G04-02.